Thermo Fisher Scientific has formed the Immuno-Oncology Consortium to enhance immunotherapy cancer research across Europe with next-generation sequencing (NGS) panels.
The consortium, which includes a group of clinical researchers from various European institutions, intends to adopt highly sensitive NGS for identifying predictive and prognostic biomarkers associated with immunotherapy of cancer.
As part of the new initiative, the firm has introduced the Ion AmpliSeq Immune Repertoire Assay Plus, TCR beta test, to detect multiple gene variants using a single panel.
